999三九品牌怎么样 申请店铺

华润三九医药股份有限公司（简称“华润三九”）是大型国有控股医药上市公司，前身为深圳南方制药厂。1999年4月21日，发起设立股份制公司。2000年3月9日在深圳证券交易所挂牌上市，股票代码000999。公司于2007年11月底正式进入华润集团。2010年2月，公司名称由“三九医药股份有限公司”正式变更为"华润三九医药股份有限公司"。

华润三九主要从事医药产品的研发、生产、销售及相关健康服务。“999”品牌是中国驰名商标。公司核心产品在国内药品市场上具有相当高的占有率和知名度。三九胃泰、999感冒灵、999皮炎平、999小儿氨酚、999正天丸、999强力枇杷露、气滞胃痛颗粒、999参附注射液、999参麦注射液、舒血宁注射液、华蟾素、999新泰林（注射用五水头孢唑啉钠）、999中药配方颗粒等，单品种年销售均超过亿元人民币。其中，999感冒灵系列销量连续五年位居感冒药市场第一，2011年实现销售额13.6亿元。

2011年，华润三九实现营业收入55.25亿元，较上年同期增长26.58%，实现了公司通过外延式发展促进业务增长的目标。由于成本费用上涨，2011年实现归属于母公司所有者的净利润7.6亿元，同比上年略有降低；经营活动产生的现金流量净额9.55亿元。截至2011年底，公司总资产为76亿元。

当前，华润三九总市值为180亿元，稳定保持在医药行业上市公司前列。上市公司及所属多家生产制造单元为国家高新技术企业。华润三九先后获评“2008年度中国上市公司百强金牛奖”、“2008年度中国上市公司价值百强”、2009年中国制药工业百强”、“2010年度中国最具竞争力医药上市公司20强”等荣誉。2011年，在中国中药协会发布首批中药行业信用评价结果，华润三九获评AAA级中药企业信用荣誉，荣列排行榜榜首。

经过20多年不懈努力，尤其是并入华润集团四年来的大力变革，华润三九现已发展成为国内大型医药类上市公司。华润三九逐步形成了自身的优势和实力。品牌优势：公司具有较强的细分市场产品品牌运作经验，“999”品牌知名度高，目标客户接受度高，是感冒药和皮肤药市场的领导品牌。近期，由世界第二大传播服务集团WPP发布的《2012中国最具价值品牌TOP50强榜单》中，“999”品牌再度入选其中。此次共有“999”、云南白药、同仁堂3个医药品牌入选。

China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned listed pharmaceutical company, formerly known as Shenzhen Southern pharmaceutical factory. On April 21, 1999, the establishment of a joint stock company was initiated. On March 9, 2000, it was listed on Shenzhen stock exchange with the stock code of 000999. The company officially entered China Resources Group at the end of November 2007. In February 2010, the company name was officially changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". CR 39 is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. "999" brand is a well-known trademark in China. The company's core products have a very high share and popularity in the domestic drug market. Sanjiu Weitai, 999 Ganmaoling, 999 piyanping, 999 paediatric aminophenol, 999 Zhengtian pill, 999 Qiangli loquat dew, Qizhi Weitong granules, 999 Shenfu injection, 999 Shenmai injection, Shuxuening injection, Cinobufacin, 999 Xintailin (cefazolin sodium pentahydrate for injection), 999 traditional Chinese medicine formula granules, etc. the annual sales of each single variety are more than RMB 100 million. Among them, the sales volume of 999 Ganmaoling series ranked first in the cold medicine market for five consecutive years, and achieved a sales volume of 1.36 billion yuan in 2011. In 2011, Cr 39 achieved an operating revenue of 5.525 billion yuan, an increase of 26.58% over the same period of the previous year, and achieved the company's goal of promoting business growth through extensive development. Due to the increase of cost, the net profit attributable to the owners of the parent company was RMB 760 million in 2011, slightly lower than the previous year; the net cash flow from operating activities was RMB 955 million. By the end of 2011, the company's total assets were 7.6 billion yuan. At present, the total market value of Cr 39 is 18 billion yuan, which is stable in the forefront of Listed Companies in the pharmaceutical industry. The listed company and its production and manufacturing units are national high-tech enterprises. China Resources 39 has been awarded the "2008 golden bull award of China's top 100 listed companies", "2008 top 100 value of China's listed companies", "2009 Top 100 pharmaceutical industry of China", "2010 Top 20 most competitive pharmaceutical listed companies of China" and other honors. In 2011, the first batch of credit evaluation results of traditional Chinese medicine industry were released in China Association of traditional Chinese medicine, and Cr 39 won the credit honor of AAA level traditional Chinese medicine enterprise, ranking first in the list. After more than 20 years of unremitting efforts, especially the great changes in four years since it was incorporated into China Resources Group, China Resources 39 has developed into a large-scale pharmaceutical listed company in China. China Resources has gradually formed its own advantages and strength. Brand advantage: the company has strong experience in brand operation of products in the market segment, "999" brand has high popularity and high acceptance of target customers. It is the leading brand in cold medicine and skin medicine market. Recently, in the list of top 50 most valuable brands in China 2012 released by WPP, the world's second largest communication service group, "999" brand has been selected again. This time, "999", Yunnan Baiyao and Tongrentang were selected.

本文链接： https://brand.waitui.com/815c90ce7.html 联系电话：0755-83360999